Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

ne million men in the United States have prostate cancer, with an estimated 186,320 new cases expected to be diagnosed in 2008, and approximately 28,660 men expected to die this year from the disease. Currently there are limited treatment options for men with advanced, metastatic prostate cancer.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. In clinical studies, patients typically received three doses of PROVENGE over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
(Date:10/20/2014)... 20, 2014 , A major ... and the delivery of care has revealed changing trends ... inequalities in the provision of healthcare services across the ... by United European Gastroenterology (UEG), have been announced today ... awareness of the burden of GI disorders across ...
(Date:10/20/2014)... Earle Martin , Chief Executive ... Ellen Teplitzky, an experienced attorney specializing in business ... has joined the firm as Director of Legal ... NDA Partners provides legal services, including research, ... top law firms and their clients in cases ...
(Date:10/19/2014)... Mass. , Oct. 19, 2014 NextCODE Health, ... the whole genome in real time, today announced the launch ... NextCODE Exchange , at the American Society of Human ... . To learn more, sign up and apply for free ... its unique features and benefits can be viewed here ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3
... 27 Carna Biosciences, Inc. ("Carna"),announced on October ... with,Shanghai Universal Biotech Company ("SUBC"). Under the terms ... of Carna,s Protein,Kinases within China., With China,s ... life sciences, major biopharmaceutical companies have now established,research ...
... 27 BioAtom Inc. (private) announced,today that it will ... October 28, 2008 at 2:30 PM PDT (5:30 PM ... California., Myron Karasik, M.B.A., C.M.C., Director of Finance, ... of Costa Mesa, CA, dedicated,to development and commercialization of ...
... CITY, Oct. 24 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... company focused on,endocrine therapy and oncology, today announced ... Market, notifying AEterna Zentaris that during the 30,consecutive ... bid price of the,Company,s common shares had closed ...
Cached Biology Technology:Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company 2BioAtom Inc. To Present at BIOCOM Investor Conference 2008 2AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price 2AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price 3
(Date:10/15/2014)... , Oct. 15, 2014 Sandata Technologies, ... home and community-based care, today announced it released ... Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™)  for ... a home health company founded in 1996 and ... . The study details the ...
(Date:10/15/2014)... Researchers have linked increased resistance to bacterial pneumonia in ... sex hormone estrogen. , Females are naturally more resistant ... of scientists has shown that increased resistance to bacterial ... nitric oxide synthase 3 (NOS3). They also show that ... the female sex hormone estrogen. , The team, lead ...
(Date:10/14/2014)... Research shows SIRT6—a protein known to inhibit the ... of skin cancers by turning on an enzyme that ... , Previously considered protective, SIRT6 is part of a ... genomic stability and prevent some of the genetic flaws ... can lead to cancer. This study, in the journal,s ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... global warming is causing the worldwide declines of amphibians ... to biologists. The findings, which contradict two widely held ... and toads and aid in their conservation. "We ... extinction event," said Peter Hudson, the Willaman professor of ...
... Greenland,s ice sheet Studies have indicated that ... increasing average summer air temperatures in southern coastal regions. ... mass from 1958 through 2008, Rignot et al. study ... sensing techniques; and surface mass balance, which is derived ...
... of DNA sequence information resulting from deciphering the human ... technological developments that have been vital in the identification ... for the development of novel genetic therapies to treat ... new genomic era heralds earlier diagnoses, greatly improved prevention ...
Cached Biology News:Global warming link to amphibian declines in doubt 2Global warming link to amphibian declines in doubt 3AGU journal highlights: Nov. 11, 2008 2AGU journal highlights: Nov. 11, 2008 3AGU journal highlights: Nov. 11, 2008 4AGU journal highlights: Nov. 11, 2008 5AGU journal highlights: Nov. 11, 2008 6AGU journal highlights: Nov. 11, 2008 7AGU journal highlights: Nov. 11, 2008 8AGU journal highlights: Nov. 11, 2008 9AGU journal highlights: Nov. 11, 2008 10Personalized medicine: Innovative online journal leads the way 2
Packaging: package with 500 l Patent/trademark/license (electronic): (r) Registered trademark of Molecular Probes...
... Rotofor purification system, 100-120 V, is used ... isoelectric focusing (IEF). The system includes both ... ml) focusing chambers, chassis, harvesting apparatus, cooling ... (pH 3-10), 60 ml syringe, colored protein ...
...
... B-Phycoerythrin Labeling Kit - NH2 is primarily ... for immunostaining and cellular proteins for tracing. ... has succinimidyl group (NHS), and can easily ... of IgG or other proteins without any ...
Biology Products: